Safety and efficacy of once-weekly efruxifermin versus placebo in non-alcoholic steatohepatitis (HARMONY): a multicentre, randomised, double-blind, placebo-controlled, phase 2b trial

医学 安慰剂 脂肪性肝炎 临床终点 胃肠病学 肝活检 内科学 纤维化 脂肪变性 代理终结点 外科 活检 脂肪肝 临床试验 替代医学 病理 疾病
作者
Stephen A. Harrison,Juan P. Frías,Guy Neff,Gary A. Abrams,K. Lucas,William Sánchez,Sudhanshu Gogia,Muhammed Y Sheikh,Cynthia Behling,Pierre Bédossa,Lan Shao,Doreen Chan,Erica Fong,Brittany de Temple,Reshma Shringarpure,Erik J. Tillman,Timothy P. Rolph,Andrew Cheng,Kitty Yale
出处
期刊:The Lancet Gastroenterology & Hepatology [Elsevier]
卷期号:8 (12): 1080-1093 被引量:44
标识
DOI:10.1016/s2468-1253(23)00272-8
摘要

Background Fibroblast growth factor 21 (FGF21) regulates metabolism and protects cells against stress. Efruxifermin is a bivalent Fc–FGF21 analogue that replicates FGF21 agonism of fibroblast growth factor receptor 1c, 2c, or 3c. The aim of this phase 2b study was to assess its efficacy and safety in patients with non-alcoholic steatohepatitis (NASH) and moderate (F2) or severe (F3) fibrosis. Methods HARMONY is a multicentre, randomised, double-blind, placebo-controlled, 96-week, phase 2b trial that was initiated at 41 clinics in the USA. Adults with biopsy-confirmed NASH, defined by a non-alcoholic fatty liver disease activity score (NAS) of 4 or higher and scores of 1 or higher in each of steatosis, ballooning, and lobular inflammation, with histological stage F2 or F3 fibrosis, were randomly assigned (1:1:1), via an interactive response system, to receive placebo or efruxifermin (28 mg or 50 mg), subcutaneously once weekly. Patients, investigators, pathologists, site staff, and the sponsor were masked to group assignments during the study. The primary endpoint was the proportion of patients with improvement in fibrosis of at least 1 stage and no worsening of NASH, based on analyses of baseline and week 24 biopsies (liver biopsy analysis set [LBAS]). A sensitivity analysis evaluated the endpoint in the full analysis set (FAS), for which patients with missing biopsies were considered non-responders. This trial is registered with ClinicalTrials.gov, NCT04767529, and is ongoing. Findings Between March 22, 2021, and Feb 7, 2022, 747 patients were assessed for eligibility and 128 patients (mean age 54·7 years [SD 10·4]; 79 [62%] female and 49 male [38%]; 118 [92%] white; and 56 [41%] Hispanic or Latino) were enrolled and randomly assigned to receive placebo (n=43), efruxifermin 28 mg (n=42; two randomised patients were not dosed because of an administrative error), or efruxifermin 50 mg (n=43). In the LBAS (n=113), eight (20%) of 41 patients in the placebo group had an improvement in fibrosis of at least 1 stage and no worsening of NASH by week 24 versus 15 (39%) of 38 patients in the efruxifermin 28 mg group (risk ratio [RR] 2·3 [95% CI 1·1–4·8]; p=0·025) and 14 (41%) of 34 patients in the efruxifermin 50 mg group (2·2 [1·0–5·0]; p=0·036). Based on the FAS (n=128), eight (19%) of 43 patients in the placebo group met this endpoint versus 15 (36%) of 42 in the efruxifermin 28 mg group (RR 2·2 [95% CI 1·0–4·8]; p=0·033) and 14 (33%) of 43 in the efruxifermin 50 mg group (1·9 [0·8–4·3]; p=0·123). The most frequent efruxifermin-related adverse events were diarrhoea (16 [40%] of 40 patients in the efruxifermin 28 mg group and 17 [40%] of 43 patients in efruxifermin 50 mg group vs eight [19%] of 43 patients in the placebo group; all events except one were grade 1–2) and nausea (11 [28%] patients in the efruxifermin 28 mg group and 18 [42%] patients in the efruxifermin 50 mg group vs ten [23%] patients in the placebo group; all grade 1–2). Five patients (two in the 28 mg group and three in the 50 mg group) discontinued due to adverse events. Serious adverse events occurred in four patients in the 50 mg group; one was defined as drug related (ulcerative esophagitis in a participant with a history of gastro-oesophageal reflux disease). No deaths occurred. Interpretation Efruxifermin improved liver fibrosis and resolved NASH over 24 weeks in patients with F2 or F3 fibrosis, with acceptable tolerability, supporting further assessment in phase 3 trials. Funding Akero Therapeutics.
最长约 10秒,即可获得该文献文件

科研通智能强力驱动
Strongly Powered by AbleSci AI
更新
大幅提高文件上传限制,最高150M (2024-4-1)

科研通是完全免费的文献互助平台,具备全网最快的应助速度,最高的求助完成率。 对每一个文献求助,科研通都将尽心尽力,给求助人一个满意的交代。
实时播报
1秒前
hhh应助小徐医生采纳,获得10
2秒前
粗暴的小熊猫完成签到 ,获得积分10
4秒前
万能图书馆应助寻雪采纳,获得10
5秒前
完美世界应助yuan采纳,获得10
5秒前
5秒前
hhhhh完成签到,获得积分10
7秒前
QP34完成签到 ,获得积分10
9秒前
尼莫完成签到,获得积分10
9秒前
9秒前
曾婉娟发布了新的文献求助10
10秒前
薰硝壤应助霖槿采纳,获得30
10秒前
曹文鹏发布了新的文献求助10
12秒前
薰硝壤应助单纯的雅香采纳,获得10
13秒前
15秒前
15秒前
17秒前
euphoria发布了新的文献求助10
17秒前
大模型应助叮咚采纳,获得10
18秒前
18秒前
852应助Apple采纳,获得10
19秒前
爆米花应助科研通管家采纳,获得10
19秒前
cctv18应助科研通管家采纳,获得10
20秒前
Orange应助科研通管家采纳,获得10
20秒前
20秒前
神勇秋白完成签到,获得积分0
20秒前
英姑应助科研通管家采纳,获得10
20秒前
曦子曦子应助科研通管家采纳,获得10
20秒前
顾矜应助科研通管家采纳,获得10
20秒前
20秒前
华仔应助科研通管家采纳,获得30
21秒前
21秒前
852发布了新的文献求助10
21秒前
曦子曦子应助科研通管家采纳,获得10
21秒前
cctv18应助科研通管家采纳,获得10
21秒前
英姑应助科研通管家采纳,获得10
21秒前
在水一方应助落后画笔采纳,获得10
21秒前
cctv18应助科研通管家采纳,获得10
21秒前
刻苦的芝应助科研通管家采纳,获得10
21秒前
Owen应助科研通管家采纳,获得10
22秒前
高分求助中
Sustainability in Tides Chemistry 1500
TM 5-855-1(Fundamentals of protective design for conventional weapons) 1000
Gerard de Lairesse : an artist between stage and studio 500
Digging and Dealing in Eighteenth-Century Rome 500
Queer Politics in Times of New Authoritarianisms: Popular Culture in South Asia 500
Livre et militantisme : La Cité éditeur 1958-1967 500
Retention of title in secured transactions law from a creditor's perspective: A comparative analysis of selected (non-)functional approaches 500
热门求助领域 (近24小时)
化学 医学 生物 材料科学 工程类 有机化学 生物化学 物理 内科学 纳米技术 计算机科学 化学工程 复合材料 基因 遗传学 催化作用 物理化学 免疫学 量子力学 细胞生物学
热门帖子
关注 科研通微信公众号,转发送积分 3061106
求助须知:如何正确求助?哪些是违规求助? 2716483
关于积分的说明 7450016
捐赠科研通 2362416
什么是DOI,文献DOI怎么找? 1252135
科研通“疑难数据库(出版商)”最低求助积分说明 607939
版权声明 596536